Experience
GlaxoSmithKline
Alphapharm
Represented GlaxoSmithKline in multiple ANDA challenges to Orange Book listed patents covering its Paxil® pharmaceutical product.
GlaxoSmithKline v. Alphapharm, 2:01-cv-01027; 2:01-cv-03364; 2:02-cv-08493, E.D. Pa., Judges Baylson, Surrick
Urologix Inc. v. Prostalund AB
ACMI Circon Corp.
Aventis Behring LLC v. Bayer Corp.
Aventis Behring LLC
Nova Design Technologies Ltd. v. Children's Medical Ventures
Children's Medical Ventures; Philips
Alzheimer's Institute of America, Inc. v. Avid Radiopharmaceuticals
Avid Radiopharmaceuticals
AstraZeneca Pharmaceuticals LP
USPTO cancels all claims for Finnegan client CRS in second CBM proceeding (in favor of)
CRS Advanced Technologies
Monta Vista
Elan Pharmaceuticals, Inc. v. Ivax Pharmaceuticals, Inc.
Elan Pharmaceuticals, Inc.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.